WHO Backs DoxyPEP: A Game-Changer for Bacterial STI Prevention Amid Resistance Worries

The World Health Organization (WHO) issued landmark guidance on May 28, 2026, officially endorsing Doxycycline Post-Exposure Prophylaxis (DoxyPEP) for men who have sex with men (MSM) and transgender women (TGW). This proactive strategy, involving taking a dose of the antibiotic doxycycline within 72 hours of unprotected sex, marks a pivotal shift in the global fight against surging bacterial sexually transmitted infections (STIs), offering a new prevention tool where traditional methods often fall short. While clinical trials consistently highlight DoxyPEP's significant effectiveness, particularly against syphilis and chlamydia, the looming shadow of antimicrobial resistance (AMR) casts a critical concern. Health authorities like the European Centre for Disease Prevention and Control (ECDC) have voiced caution, emphasizing the potential for widespread use to accelerate resistance in STI pathogens, especially Neisseria gonorrhoeae, and even in 'bystander bacteria' within the body. This delicate balance between immediate prevention benefits and long-term public health threats is at the heart of the current global debate. Looking ahead, the WHO stresses that DoxyPEP must be integrated not as a standalone solution, but within a comprehensive sexual health approach that includes regular STI testing, consistent condom use, and robust AMR surveillance. As national programs consider implementation, ongoing monitoring of both STI incidence and evolving resistance patterns will be crucial to tailor this new recommendation effectively. The coming months will likely see further guidance from the WHO, as countries navigate maximizing DoxyPEP's benefits while diligently mitigating its inherent risks.